» Authors » Han-Yu Deng

Han-Yu Deng

Explore the profile of Han-Yu Deng including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 110
Citations 547
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
12.
Huang W, Deng H, Li D, Li P, Xu K, Zhang Y, et al.
J Cardiothorac Surg . 2022 Sep; 17(1):240. PMID: 36171612
Background: Primary pulmonary osteosarcoma (PPOS) is an uncommon malignancy originating from the lung with low incidence, and its clinical characteristics and prognosis have not been systematically reported. Therefore, we aimed...
13.
Deng H, Qiu X, Zhu D, Tang X, Zhou Q
J Cancer Res Clin Oncol . 2022 Sep; 149(8):4623-4628. PMID: 36171456
Purpose: Neoadjuvant therapy followed by surgical resection is one of the preferred treatment option for locally advanced non-small cell lung cancer (NSCLC). For patients with mesenchymal-epithelial transition (MET) factor exon...
14.
Huang W, Deng H, Ren Z, Xu K, Wang Y, Tang X, et al.
BMJ Open . 2022 Aug; 12(8):e056043. PMID: 36038163
Introduction: Lung cancer was the most common malignancy and the leading cause of cancer-related death in China or worldwide, and surgery is still the preferred treatment for early-stage non-small cell...
15.
Peng L, Shang Q, Deng H, Liu Z, Li W, Wang Y
Asian J Surg . 2022 Aug; 46(2):683-687. PMID: 35918226
Lymph node dissection is a vital part of surgical treatment for early-stage non-small cell lung cancer (NSCLC). Lobectomy with systematic lymph node dissection (SLND) still remains the gold standard surgical...
16.
Ren Z, Deng H, Huang W, Zhou Q
Interact Cardiovasc Thorac Surg . 2022 Jun; 35(2). PMID: 35748763
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether intraoperative conversions to thoracotomy have an impact on long-term survival for...
17.
18.
Huang W, Deng H, Wu X, Xu K, Li P, Lin M, et al.
Asian J Surg . 2022 May; 46(1):385-393. PMID: 35525696
Objective: With the increasing incidence of stage IA lung cancer ≤1 cm in size, the optimal primary treatment remains to be controversial, and thus, we compared the survival of these...
19.
Deng H, Jia B, Tang X, Zhou Q
ANZ J Surg . 2022 Apr; 93(1-2):349-350. PMID: 35488740
No abstract available.
20.
Huang W, Deng H
Ann Thorac Surg . 2022 Apr; 115(3):798-799. PMID: 35472405
No abstract available.